“We found the active pharmaceutical ingredients which could not be accounted for,” says Fafudi.
Several finished semaglutide products, as well as products containing tirzepatide, were also discovered on site.
Fafudi says combinations of tirzepatide and semaglutide are still undergoing clinical trials and have not yet been approved for use.
READ: SAHPRA recalls contraceptive tablets due to quality issue
“These are schedule four substances which, in the scale at which they are produced, should be registered by SAHPRA,” says Fafudi.
The plant should also be licensed by SAHPRA for manufacturing, which it is not.